Menu

Path Finding

Biochemistry reveals the missing link in a pathway that archaea and some bacteria use to generate essential compounds.

Mar 1, 2014
Abby Olena

CHARTING THE COURSE: Eukaryotes use the classic mevalonate (MVA) pathway (blue) to produce isopentenyl diphosphate (IPP), a precursor molecule necessary for cholesterol biosynthesis. The discovery of the enzymes isopentenyl phosphate kinase (IPK) and, most recently, mevalonate phosphate decarboxylase (MPD) chart an alternate route for at least some bacteria and archaea. Statin drugs limit cholesterol production by interfering with IPP production. Abbreviations: phosphomevalonate kinase (PMK), diphosphomevalonate decarboxylase (MDD)MODIFIED FROM eLIFE, doi:10.7554/eLife.00672.002, 2013

EDITOR'S CHOICE IN BIOCHEMISTRY

The paper
N. Dellas et al., “Discovery of a metabolic alternative to the classical mevalonate pathway,” eLife, doi:10.7554/eLife.00672.002, 2013.

The first steps in the biosynthesis of cholesterol are collectively called the mevalonate (MVA) pathway and result in the generation of isopentenyl diphosphate (IPP). The synthesis of IPP is essential in all organisms as a starting point for the formation of isoprenoids—a large group of compounds that include cholesterol, hormones, and signaling molecules, and that chemists have tapped for vitamins, fragrances, flavorings, and pigments, among hundreds of other uses. Statin drugs target the MVA pathway and limit the output of IPP to lower cholesterol levels.

Bacteria, archaea, and eukaryotes take different tacks to produce IPP. Eukaryotes generally use the classic five-step MVA pathway, while plant chloroplasts and most bacteria employ a distinct route called the DXP or MEP pathway. In archaea, the first three steps of the MVA pathway overlap with the eukaryotic route, but the discovery of the enzyme isopentenyl phosphate kinase (IPK) in 2006 revealed a slightly different ending. In the final step of this alternate pathway, IPK adds a phosphate to isopentenyl phosphate (IP)—IPP’s direct precursor. The enzyme catalyzing the step preceding this event, however, remained undiscovered.

HHMI investigator Joseph Noel of the Salk Institute for Biological Studies in La Jolla, California, and colleagues were interested in reengineering IPK to generate isoprenoids more efficiently. Along with studying plant metabolite evolution, Noel is also the founder of two companies that commercialize isoprenoids.

After solving the crystal structure of IPK in 2010, Noel’s graduate student Nikki Dellas experienced a moment of what Noel calls “serendipity in science.” The crystal structure revealed residues important for the enzyme’s function. Dellas then used these “signature sequences” to find and biochemically characterize seven putative homologs of IPK across all three domains of life. Each homolog was capable of phosphorylating IP. “This particular activity is widespread in nature,” says Noel. “That was completely unexpected.”

As the researchers studied IPK, a not-well-characterized phylum of green, non-sulfur bacteria called Chloroflexi caught their attention. Initial examination of the genome of one Chloroflexi species, Roseiflexus castenholzii, indicated that the microbes used the classic, eukaryotic MVA pathway. But a closer look showed that this species also encoded a functional IPK homolog and was missing one gene from the MVA route. This suggested that the bacteria were following a different biochemical course to generate IPP.

Last year the team identified the missing piece of the R. castenholzii puzzle: an enzyme, mevalonate phosphate decarboxylase (MPD), which catalyzes the penultimate step of IPP production. Their discovery uncovered a unique branch of the MVA pathway, one that could also fill in the gap of how archaea produce IPP. Another group later confirmed that at least one species of archaea indeed uses MPD.

“[This work] is really unique and exciting. What it actually suggests is that there’s a lot of diversity in [isoprenoid] biosynthesis in living organisms,” says Claudia Vickers, a senior research fellow at the University of Queensland. “There are probably variations on those pathways in all kingdoms of life.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!